fbpx
close read more

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Press contact :

01.55.72.70.10 – presse@servier.com

Press release

Press release
26/09/2022
Servier exercises the exclusive worldwide license option of their collaboration program with Oncodesign Precision Medicine (OPM) on Parkinson’s disease
Press release
22/09/2022
Oncodesign Precision Medicine (OPM) and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment
Press release
22/09/2022
Servier Accelerates its Digital Transformation with Google Cloud
Press release
08/09/2022
Servier presents pipeline of innovative oncology projects at ESMO International Congress
Press release
24/08/2022
GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
Press release
15/06/2022
Servier appoints Angelo Paci as Oncology & Immuno-Oncology Program Leader
Press release
06/05/2022
Servier appoints Nicolas Lévy as Chief Scientist Rare Diseases
Press release
27/04/2022
Appointment of Walid S. Kamoun, PhD. MSc., Global Head of Servier R&D Oncology
Press release
26/01/2022
Servier partners with French start-up Epigene Labs to launch a new application in the field of oncology